Abediterol/AZD 7594
Alternative Names: Abediterol/AZ13189620; AZD7594/abediterolLatest Information Update: 28 Dec 2019
At a glance
- Originator AstraZeneca
- Class Antiasthmatics; Bronchodilators; Quinolines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Germany (Inhalation, Powder)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Germany (Inhalation, Powder)
- 18 May 2018 Pharmacokinetics and adverse events data from a phase I trial in Asthma presented at the 114th International Conference of the American Thoracic Society